Business ❯ Pharmaceutical Industry

Drug Manufacturers

Pricing Strategies Novo Nordisk Pricing Agreements Eli Lilly Pfizer Market Dynamics AstraZeneca Market Competition Price Negotiations Kenvue Merck Market Impact Price Negotiation Novo Nordisk and Eli Lilly Price Agreements Discount Programs Eli Lilly and Novo Nordisk Cost Reduction Strategies Profit Margins Market Regulations Negotiation Strategies Amgen Purdue Pharma Negotiation Practices Market Trends Market Regulation Revenue Impact Price Negotiation Lawsuits Negotiation Processes Profitability Healthcare Providers Market History Opioid Distributors Legal Settlements Rebates PhRMA Distribution Companies Weight Loss Drugs Negotiation Process Reformulation GSK Weight-loss Drugs Johnson & Johnson CEOs Bristol Myers Squibb Medication Pricing Medicare Part D Boehringer Ingelheim GLP-1 Receptor Agonists Market Reactions Research and Development Sanofi Bristol Myers and Pfizer Regulatory Challenges Lobbying Patient Information Market Strategies Bayer Danco Laboratories Corporate Responsibility Rebate Plans Compliance Lilly Noro Nordisk Collusion Market Practices Price Increases Pfizer Inc. Product Quality Market Access IVF Drugs Merck KGaA EMD Serono Novo Nordisk Inc. Market Pricing AbbVie Insulin Manufacturers Negotiations Legal Appeals Agreements Cost Management Market Agreements Regulatory Compliance Mifepristone Producers Generic Drugs Mifepristone Production Compliance Standards Abbvie and Genentech AbbVie and Genentech Government Relations Rebate Programs Vitruvias Therapeutics Eli Lilly and Company

FDA Elevates Vitruvias Thyroid Tablet Recall to Class I

The agency says a single lot was found potentially superpotent, creating a reasonable probability of serious harm.

Lawsuits Over GLP‑1 Drugs Mount After Reports of Rare Sudden Vision Loss

Trump Extends Most-Favored-Nation Drug Prices to Every State Medicaid Program

Trump Adds Nine Drugmakers to Most‑Favored‑Nation Pricing Program

U.S. Prescription Drug Prices Drop Most Since 1963 as White House Claims Credit

HRSA Reworks 340B Pilot to Let Drugmakers Offer Voluntary Rebates

Medicare Opens $50 GLP-1 Bridge as Doctors Warn of Patient Surge

Supreme Court Rejects Drugmakers’ Appeals Over Medicare Price Talks

White House Projects $529 Billion in Savings From Trump’s MFN Drug Pricing Plan

AbbVie, Genentech Join TrumpRx With Deep Discounts on Humira and Xofluza

Drug-Cost Anxiety Hits New High in KFF Poll as TrumpRx Sees Limited Reach

Trump Presses Congress to Lock In Drug Pricing Deals as He Showcases TrumpRx at State of the Union

Democratic Report Puts TrumpRx Under Fresh Scrutiny as Analyses Question Real-World Savings

Lawmakers Seek Transparency as TrumpRx Faces Questions on Who Saves

TrumpRx Debuts With 43 Discounted Brand Drugs as Analyses Flag Cheaper Generics and Limits

TrumpRx Launches, Offering Discounted Brand‑Name Drugs Through U.S. Portal

GLP-1 Weight-Loss Push Intensifies as Novo Leads Ads and Wegovy Pill Drives Telehealth Uptake

AbbVie Strikes Trump Drug-Pricing Deal, Pledges $100 Billion, Wins 3-Year Tariff Reprieve

Oregon Sues Insulin Makers and PBMs, Alleging $900 Million Pricing Scheme

Indiana Sues Eli Lilly, Alleging Scheme to Inflate Insulin Prices